- Home
- JELD vs NYXH Comparison
JELD vs NYXH Comparison
Compare JELD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | NYXH |
|---|---|---|
| Founded | 1960 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Forest Products | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 161.9M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JELD | NYXH |
|---|---|---|
| Price | $1.17 | $1.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.43 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 1.8M | 217.1K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | $2.06 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $1.26 |
| 52 Week High | $6.98 | $8.59 |
Technical Indicators
Market Signals| Indicator | JELD | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 35.20 |
| Support Level | $0.93 | $1.26 |
| Resistance Level | $2.06 | $1.70 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 6.89 | 9.50 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.